PCSK9 inhibitor alleviates experimental pulmonary fibrosis-induced pulmonary hypertension via attenuating epithelial-mesenchymal transition by suppressing Wnt/β-catenin signaling in vivo and in vitro
BackgroundThe co-occurrence of pulmonary hypertension (PH) in patients with pulmonary fibrosis (PF) is linked to a more unfavorable prognosis and increased mortality compared to PF cases without PH. Early intervention and comprehensive management are pivotal for improving survival outcomes. Proprote...
Autors principals: | Jiancheng Lin, Zetao Pan, Jiayan Sun, Xiaowan Wang, Di Yin, Cunyang Huo, Qiang Guo |
---|---|
Format: | Article |
Idioma: | English |
Publicat: |
Frontiers Media S.A.
2024-12-01
|
Col·lecció: | Frontiers in Medicine |
Matèries: | |
Accés en línia: | https://www.frontiersin.org/articles/10.3389/fmed.2024.1509168/full |
Ítems similars
-
Increased serum albumin corrected anion gap levels are associated with poor prognosis in septic patients with liver cirrhosis
per: Zetao Pan, et al.
Publicat: (2024-09-01) -
Fatty acid-binding protein 5 aggravates pulmonary artery fibrosis in pulmonary hypertension secondary to left heart disease via activating wnt/β-catenin pathway
per: Qian Lei, et al.
Publicat: (2022-09-01) -
PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis
per: Ding-Qiang Chen, et al.
Publicat: (2024-07-01) -
Knockdown of YAP inhibits growth in Hep-2 laryngeal cancer cells via epithelial-mesenchymal transition and the Wnt/β-catenin pathway
per: Xiaomin Tang, et al.
Publicat: (2019-07-01) -
FERMT3 mediates cigarette smoke-induced epithelial–mesenchymal transition through Wnt/β-catenin signaling
per: Xiaoshan Su, et al.
Publicat: (2021-11-01)